Shield Thera Share News (STX)

EARNINGS AND TRADING: Software Circle & Beximco report higher revenue

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

UK earnings, trading statements calendar - next 7 days

LONDON MARKET CLOSE: FTSE 100 takes hit ahead of FOMC minutes

(Alliance News) - Stock prices in London closed lower on Wednesday, as investors anxiously look ahead to this evening's Federal Open Market Committee meeting minutes.

Shield Therapeutics sinks as strong performance marred by data issues

(Alliance News) - Shield Therapeutics PLC on Wednesday said that it was expecting stellar results for 2023, but this success was overshadowed by a mistake in the company's previous prescription forecasts.

IN BRIEF: Shield Therapeutics hires former Akili leader as new CFO

Shield Therapeutics PLC - Commercial-stage pharmaceutical company focused on iron deficiency product Accrufer - Hires Santosh Shanbhag as chief financial officer, effective next Tuesday. He replaces Hans-Peter Rudolf, who left Shield in October to pursue new opportunities. Shanbhag was previously CFO of Nasdaq-listed Akili Inc, which he "helped transform...from a private to a public entity". Before this, he held various senior finance leadership roles at Vertex Pharmaceuticals Inc, including as Head of International Finance & Accounting.

TRADING UPDATES: Comptoir opens restaurant; Intercede wins contract

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Shield Therapeutics reports strong US progress

(Sharecast News) - Iron deficiency-focussed pharmaceuticals company Shield Therapeutics announced significant achievements in the US commercialisation of Accrufer on Thursday.

IN BRIEF: Shield Therapeutics Chief Financial Officer Rudolf to leave

Shield Therapeutics PLC - commercial-stage pharmaceutical company focusing on its iron deficiency product Accrufer - Chief Financial Officer Hans-Peter Rudolf will leave the company next week Friday to pursue other opportunities. The firm's company controller, Paul Spoors, will take on the CFO role on an interim basis. Shield says it has engaged an executive search firm to identify a new CFO.

AIM WINNERS & LOSERS: Windward sees high contracting activity levels

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Thursday.

TRADING UPDATES: Aston Martin CEO ups stake; Alkemy's lithium deal

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Shield Therapeutics completes USD20 million SWK financing

(Alliance News) - Shield Therapeutics PLC on Tuesday said it has now completed its USD20 million senior secured debt facility from SWK Funding LLC.

UPDATE: Shield Therapeutics completes GBP5 million share placing

(Alliance News) - Shield Therapeutics PLC on Thursday announced steps to improve its financial situation, as it revealed a slightly reduced loss in the first half of 2023.

Shield Therapeutics raises funds for US sales push as loss narrows

(Alliance News) - Shield Therapeutics PLC on Thursday announced steps to improve its financial situation, as it revealed a slightly reduced loss in the first half of 2023.

UK earnings, trading statements calendar - next 7 days

IN BRIEF: Shield Therapeutics changes reporting currency to US dollars

Shield Therapeutics PLC - Gateshead Quays, England-based commercial stage pharmaceutical company focused on the commercialisation of its oral therapy for iron deficiency - Says it will change reporting currency to US dollars from pound sterling from 2023 results. Says the interim results for the first half of 2023 will include condensed and consolidated US dollar financial information for the period and full-year 2022.